🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Reflections on the demand for PSMA- and SSTR-targeted radiopharmaceutical therapies: Why we were wrong (and why we will be right eventually). ow.ly/7ypf50VgaeM #RPTherapy #NuclearMedicine #Theranostics Jeremie Calais Lisa Bodei, MD, PhD Johannes Czernin

⁶⁸Ga-FZ-NR-1 is an innovative radiotracer that shows exceptional specificity and safety in its first PET/CT imaging study of Nectin-4 targeting patients with triple-negative #BreastCancer. ow.ly/eNZn50V4aKs #NuclearMedicine #MolecularImaging #TNBC

Very insightful discussion with a lot of learning points for me !

Green nuclear medicine and theranostics: debate and discussion. ow.ly/pMGa50VgahK #NuclearMedicine #Theranostics #MolecularImaging Ken Herrmann

SPECT deserves RESPECT: The potential of SPECT/CT to optimize patient outcomes with theranostics therapy. ow.ly/Tg2950Vgaij #NuclearMedicine #Theranostics #RPTherapy Louise Emmett

The PET index, a marker of the weight of fibroinflammatory activity, is predictive of relapse-free survival of IgG4-RD. ow.ly/jeGZ50VjuEx #NuclearMedicine #Petscan #IG4RD

Tumor dosimetry in PSMA therapy: A #VISION substudy analysis. Ken Herrmann joins Oliver Sartor, MD discussing tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in #ProstateCancer patients. #FullVideo on UroToday > bit.ly/4gmFfZE

FDA expands Pluvicto use in PSMA+ mCRPC before chemo. U.S. FDA Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation OncoAlert

JUST IN: U.S. FDA expands Lu-PSMA metastatic castration-resistant prostate cancer indication: now in Taxane-Naive population. Approval based on PSMAfore trial open Dana-Farber Lank Center for Genitourinary Oncology -rPFS 9.3 vs. 5.6mos (HR: 0.41) -OS HR 0.91 Through ASCO FDA alerts.

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication fda.gov/drugs/resource… The U.S. FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer (mCRPC)

#NEWS: Welcome to our new chief medical officer, Phillip Koo, MD! Read the full release: bit.ly/3G0SBOD #NewHire #MedX #MedEd

An interesting read: Self-citation among highly cited #NuclearMedicine and #MedicalImaging researchers. ow.ly/cPUC50Vjv2c Obada Al-leimon Malik Juweid

The very first episode of the JNM Podcast covered the future of FAPI – fibroblast activation protein inhibitors – in the treatment of cancer. Catch up on the discussion and the predictions about the future of FAPI and its clinical success: youtu.be/C_VP9E1QDdQ?si…

PARP Inhibitor resistance mechanisms in #ProstateCancer. Professor Johann De Bono The ICR discusses a decade of research on #PARPi resistance! Findings from the #TOPARP trials show BRCA2/PALB2 tumors restore DNA repair via POLθ, driving resistance. Could PARP + POLθ

¹⁸F-FES PET is a successful biomarker for predicting the likelihood of success of endocrine therapy in patients with ER-positive #BreastCancer. ow.ly/WPMt50Vjv9Q #NuclearMedicine #PETscan Ashwin Singh Parihar, MBBS, MD

Viktor Grünwald Ken Herrmann CD70-targeted cancer theranostics: Progress and challenges: Med cell.com/med/fulltext/S…

A good reading material if you have an interest in CD70-targeted cancer theranostics. Great collaboration with Ken Herrmann Viktor Grünwald, 👏👏👏. CD70-targeted cancer theranostics: Progress and challenges: Med cell.com/med/fulltext/S…

Combined use of ⁶⁸Ga-RM26 PET/CT and ⁶⁸Ga-PSMA-617 PET/CT achieved higher diagnostic sensitivity for detecting lymph node metastases in #ProstateCancer with minimal loss of specificity. ow.ly/rlpP50VnjMn #NuclearMedicine

Out now … JNM podcast edition #10. All you need to know about metabolic PET biomarkers beyond SUVmean and SUVmax. Irène Buvat JNM SNMMI Johannes Czernin youtube.com/watch?v=paszMI…

Absorbed doses calculated from 360° CZT SPECT are globally comparable to those from conventional SPECT, but CZT SPECT/CT has the advantage of shorter recording times and actual whole-body coverage. ow.ly/PasI50VnjNx #NuclearMedicine CHRU de Nancy